` GNTA (Genenta Science SPA) vs S&P 500 Comparison - Alpha Spread

GNTA
vs
S&P 500

Over the past 12 months, GNTA has underperformed S&P 500, delivering a return of -77% compared to the S&P 500's +14% growth.

Stocks Performance
GNTA vs S&P 500

Loading
GNTA
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
GNTA vs S&P 500

Performance Gap Between GNTA and GSPC
HIDDEN
Show

Performance By Year
GNTA vs S&P 500

Loading
GNTA
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Genenta Science SPA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Genenta Science SPA
Glance View

Market Cap
17.1m USD
Industry
Biotechnology

Genenta Science SpA engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. The company is headquartered in Milan, Milano and currently employs 4 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.

GNTA Intrinsic Value
HIDDEN
Show
Back to Top